Distinguished in Dementia

Ryoko Ihara

Itabashi, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Dementia
Itabashi, JP 
OverviewLocationsClinical Research

Overview

Ryoko Ihara practices in Itabashi, Japan. Ms. Ihara is rated as a Distinguished expert by MediFind in the treatment of Dementia. Her top areas of expertise are Alzheimer's Disease, Dementia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Primary Lateral Sclerosis.

Her clinical research consists of co-authoring 52 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 42 articles and participated in 2 clinical trials in the study of Dementia.

Gender
Female

Locations

Itabashi, Japan
Other Locations
Tokyo, Japan
Hongo, 1138655, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: E2814, Lecanemab
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

52 Total Publications

Property difference in Mini-Mental State Examination Serial Sevens and World Backwards: Analysis using item response theory.
Property difference in Mini-Mental State Examination Serial Sevens and World Backwards: Analysis using item response theory.
Journal: Journal of Alzheimer's disease : JAD
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ihara's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile